Cargando…

Interferon-γ Release Assay Performance in Pediatric Tuberculosis Disease in California

BACKGROUND: Interferon Gamma Release Assays (IGRAs) and Tuberculin Skin Tests (TSTs) are important adjunctive pediatric TB diagnostics. This study analyzes the use and performance of IGRAs in children diagnosed with active TB disease in a high-resource, low-incidence setting. METHODS: We retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kay, Alexander, Islam, Shamim, Wendorf, Kristen, Westenhouse, Janice, Barry, Pennan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630727/
http://dx.doi.org/10.1093/ofid/ofx163.1640
_version_ 1783269278264328192
author Kay, Alexander
Islam, Shamim
Wendorf, Kristen
Westenhouse, Janice
Barry, Pennan
author_facet Kay, Alexander
Islam, Shamim
Wendorf, Kristen
Westenhouse, Janice
Barry, Pennan
author_sort Kay, Alexander
collection PubMed
description BACKGROUND: Interferon Gamma Release Assays (IGRAs) and Tuberculin Skin Tests (TSTs) are important adjunctive pediatric TB diagnostics. This study analyzes the use and performance of IGRAs in children diagnosed with active TB disease in a high-resource, low-incidence setting. METHODS: We retrospectively reviewed cases of children reported with TB to the California Department of Public Health (CDPH) Tuberculosis Registry during 2010–2015. Our cohort included 778 children, after excluding 68 without an IGRA or TST reported. We analyzed case characteristics associated with test selection and performance, and measured IGRA test sensitivity in children with laboratory confirmed TB disease. RESULTS: Of the 778 cases of pediatric TB reported, 360 were laboratory confirmed. Children tested with IGRAs were more likely foreign-born, aged ≥5 years, to have extrapulmonary disease only, and be laboratory confirmed, than those tested with TST. Children aged <2 years with confirmed disease were less likely to have a positive IGRA [PRR 0.72 (95% CI 0.55, 0.93] than children ≥2 years. Indeterminate IGRAs were associated with age <1 year [PRR 9.23, 95% CI 2.87, 29.8) and central nervous system (CNS) disease (PRR 2.69, 95% CI 1.06, 6.86) on multivariate analysis suggesting an association with severe disease. IGRA and TST sensitivity were similar in children <5 years with confirmed disease and test concordance was high in this age group, but sensitivity was <87% for both tests among children aged <2 years. IGRA was more sensitive than TST among children aged 5–18 years (96%, 95% CI 88%-99% vs. 83%, 95% CI 72–91%, P = 0.012). CONCLUSION: Children presenting with TB symptoms and disseminated disease were more likely to be tested by IGRA than TST. In children <5 years, IGRA sensitivity is similar to TST, but sensitivity of both tests are reduced in children <2 years. Indeterminate results are higher, particularly in <1 year-olds and in CNS disease. In children aged ≥5 years with laboratory confirmed TB, IGRA has greater sensitivity than TST, and should be considered the preferred immunodiagnostic test. Our data suggest that IGRA is underutilized in this population. DISCLOSURES: S. Islam, Qiagen: Speaker’s Bureau, Speaker honorarium and travel support
format Online
Article
Text
id pubmed-5630727
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-56307272017-11-07 Interferon-γ Release Assay Performance in Pediatric Tuberculosis Disease in California Kay, Alexander Islam, Shamim Wendorf, Kristen Westenhouse, Janice Barry, Pennan Open Forum Infect Dis Abstracts BACKGROUND: Interferon Gamma Release Assays (IGRAs) and Tuberculin Skin Tests (TSTs) are important adjunctive pediatric TB diagnostics. This study analyzes the use and performance of IGRAs in children diagnosed with active TB disease in a high-resource, low-incidence setting. METHODS: We retrospectively reviewed cases of children reported with TB to the California Department of Public Health (CDPH) Tuberculosis Registry during 2010–2015. Our cohort included 778 children, after excluding 68 without an IGRA or TST reported. We analyzed case characteristics associated with test selection and performance, and measured IGRA test sensitivity in children with laboratory confirmed TB disease. RESULTS: Of the 778 cases of pediatric TB reported, 360 were laboratory confirmed. Children tested with IGRAs were more likely foreign-born, aged ≥5 years, to have extrapulmonary disease only, and be laboratory confirmed, than those tested with TST. Children aged <2 years with confirmed disease were less likely to have a positive IGRA [PRR 0.72 (95% CI 0.55, 0.93] than children ≥2 years. Indeterminate IGRAs were associated with age <1 year [PRR 9.23, 95% CI 2.87, 29.8) and central nervous system (CNS) disease (PRR 2.69, 95% CI 1.06, 6.86) on multivariate analysis suggesting an association with severe disease. IGRA and TST sensitivity were similar in children <5 years with confirmed disease and test concordance was high in this age group, but sensitivity was <87% for both tests among children aged <2 years. IGRA was more sensitive than TST among children aged 5–18 years (96%, 95% CI 88%-99% vs. 83%, 95% CI 72–91%, P = 0.012). CONCLUSION: Children presenting with TB symptoms and disseminated disease were more likely to be tested by IGRA than TST. In children <5 years, IGRA sensitivity is similar to TST, but sensitivity of both tests are reduced in children <2 years. Indeterminate results are higher, particularly in <1 year-olds and in CNS disease. In children aged ≥5 years with laboratory confirmed TB, IGRA has greater sensitivity than TST, and should be considered the preferred immunodiagnostic test. Our data suggest that IGRA is underutilized in this population. DISCLOSURES: S. Islam, Qiagen: Speaker’s Bureau, Speaker honorarium and travel support Oxford University Press 2017-10-04 /pmc/articles/PMC5630727/ http://dx.doi.org/10.1093/ofid/ofx163.1640 Text en © The Author 2017. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Kay, Alexander
Islam, Shamim
Wendorf, Kristen
Westenhouse, Janice
Barry, Pennan
Interferon-γ Release Assay Performance in Pediatric Tuberculosis Disease in California
title Interferon-γ Release Assay Performance in Pediatric Tuberculosis Disease in California
title_full Interferon-γ Release Assay Performance in Pediatric Tuberculosis Disease in California
title_fullStr Interferon-γ Release Assay Performance in Pediatric Tuberculosis Disease in California
title_full_unstemmed Interferon-γ Release Assay Performance in Pediatric Tuberculosis Disease in California
title_short Interferon-γ Release Assay Performance in Pediatric Tuberculosis Disease in California
title_sort interferon-γ release assay performance in pediatric tuberculosis disease in california
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630727/
http://dx.doi.org/10.1093/ofid/ofx163.1640
work_keys_str_mv AT kayalexander interferongreleaseassayperformanceinpediatrictuberculosisdiseaseincalifornia
AT islamshamim interferongreleaseassayperformanceinpediatrictuberculosisdiseaseincalifornia
AT wendorfkristen interferongreleaseassayperformanceinpediatrictuberculosisdiseaseincalifornia
AT westenhousejanice interferongreleaseassayperformanceinpediatrictuberculosisdiseaseincalifornia
AT barrypennan interferongreleaseassayperformanceinpediatrictuberculosisdiseaseincalifornia